We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » TriMed Notified on MDRs, CAPAs After Device Failure Required Surgery

TriMed Notified on MDRs, CAPAs After Device Failure Required Surgery

September 16, 2016

TriMed, a maker of implantable bone fixation systems, failed to report a device failure that required surgery to remove the device, according to an FDA warning letter.

In February 2014, the company learned about the breakage of an implanted fixation plate, which was associated with the need for surgery, according to the June 30 letter. But the Santa Clarita, Calif., company had not submitted an MDR for the event at the time of the FDA’s March inspection.

Posted on the FDA’s website Aug. 2, the warning letter cites two other complaints that linked the company’s osteotomy device and pin plate with a malfunction.

It notes that a malfunction of long-term implantable devices is reportable. However, TriMed did not submit MDR reports within 30 days of becoming aware of the events.

No Evidence

Additionally, the FDA saw “no evidence to justify whether the malfunctions would not be likely to cause or contribute to a death or serious injury, if they were to recur.”

The company did not set up systems in its MDR procedure for timely and effective identification, communication and evaluation of events that might fall under MDR requirements.

Further, TriMed’s nonconforming product procedure did not require non-conformances to be evaluated to see if an investigation was needed, and it did not require the company to document any investigations that were conducted.

Corrective and preventive action procedures also drew the FDA’s attention during the inspection.

In September 2015, TriMed initiated a CAPA referencing non-locking semi-tubular screw plate screws that were passing through the hole of the semi-tubular bone plates. It received plates from the field during that month but did not submit a written report of the removal to the FDA, the letter says.

TriMed’s CAPA procedures did not include a requirement to analyze sources of quality data, including complaints documented in the error log, non-conformances documented in the material review board log and returned products documented in the returned goods authorization log.

Missing Documentation

In addition, one CAPA was initiated in September 2015 to address complaints of non-locking screws that were passing through the hole of the plate.

The CAPA appeared to have been implemented in early October 2015 and deemed effective in February 2016; however, there was no documentation to show the corrective action — revising the dimension of the screw hole — was effective.

The corrective action plan notes that other bone plates using the same threaded screw hole could have the same issue, but the CAPA does not list the affected products or provide documentation that effective corrective actions were taken for all affected products. Meanwhile, TriMed did not document the failure mode of non-locking screws passing through the hole of bone plates during surgeries in its risk analysis for the Supracondylar Elbow Implant System. The warning letter also notes that some finished products shipped to a customer did not include records showing completion of certain activities required in the device master record for the Wrist Fixation System, Radiocarpal Fusion System and Ulnar Osteotomy System.

TriMed told QMN that the company has taken all the necessary actions and submitted the required documentation within the FDA’s deadline.

Five key areas account for 25 percent of all Form 483 observations the FDA issues devicemakers in a given year. Avoid that label by purchasing a copy of  Troubleshooting Your Quality System: A Guide to Five Devicemaker Quality Compliance Traps and you’ll have an unmatched source of critical information to ensure you’re prepared when investigators come knocking.

View today's stories

Medical Devices Inspections and Audits

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing